Maxcyte Inc Revenue Growth Rates (MXCT), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Maxcyte inc   (NASDAQ: MXCT)
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 

MXCT's Revenue Growth by Quarter and Year

Maxcyte Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/MXCT/growth
https://api.csimarket.com/api/v1/companies/MXCT/fundamentals
https://api.csimarket.com/api/v1/companies/MXCT/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
MXCT Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 10.15
2nd Quarter June 7.27
1st Quarter March 9.65
FY 27.07

MXCTs Annual Revenue
Maxcyte Inc 's Revenue in the fiscal year 2025 $ 33.03 millions
Maxcyte Inc 's Revenue in the fiscal year 2024 $ 38.63 millions
Maxcyte Inc 's Revenue in the fiscal year 2023 $ 41.29 millions
Maxcyte Inc 's Revenue in the fiscal year 2022 $ 44.26 millions
Maxcyte Inc 's Revenue in the fiscal year 2021 $ 33.89 millions




MXCT Revenue third quarter 2026 Y/Y Growth Comment
Maxcyte inc achieved in the third quarter 2026, above Company average Revenue rise of 48.64% year on year, to $ 10.15 millions.

Looking into third quarter 2026 results within Medical Laboratories industry 27 other companies have achieved higher Revenue growth. While Maxcyte Inc ' s Revenue jump of 48.64% ranks overall at the positon no. 3013 in the third quarter 2026.


MXCT Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 48.64 %
2nd Quarter June -14.57 %
1st Quarter March -7.12 %
FY   -

Financial Statements
Maxcyte Inc 's third quarter 2026 Revenue $ 10.15 millions MXCT's Income Statement
Maxcyte Inc 's third quarter 2025 Revenue $ 6.83 millions Quarterly MXCT's Income Statement


MXCT Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 39.64 %
2nd Quarter June -24.66 %
1st Quarter March 32.19 %
FY (Year on Year)   -


Back to MXCT Growth rate Comparisons >> Back to MXCT Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #28
Healthcare Sector #414
Overall #3013

Revenue Y/Y Growth Statistics
High Average Low
30.59 % -0.13 % -24.52 %
(Dec 31 2022)   (Sep 30 2025)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #28
Healthcare Sector #414
Overall #3013
Revenue Y/Y Growth Statistics
High Average Low
30.59 % -0.13 % -24.52 %
(Dec 31 2022)   (Sep 30 2025)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Maxcyte Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
110.81 % 7.01 % -54.44 %
(Dec 31 2020)  


MXCT's III. Quarter Q/Q Revenue Comment
Maxcyte inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 39.64%, to $ 10.15 millions, from $7.27 millions in the second quarter.
MXCT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Maxcyte Inc 's Revenue growth quarter on quarter, overall rank is 3392.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #32
Healthcare Sector #469
Overall #3392
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #32
Healthcare Sector #469
Overall #3392
Revenue Q/Q Growth Statistics
High Average Low
110.81 % 7.01 % -54.44 %
(Dec 31 2020)  


MXCT's III. Quarter Q/Q Revenue Comment
Maxcyte inc achieved in the III. Quarter 2026 above company average sequential Revenue jump of 39.64%, to $ 10.15 millions, from $7.27 millions in the second quarter.
MXCT is undergoing a remarkable growth, with claiming higher then normal increase, and additionally increasing rate.

Within Medical Laboratories industry 31 other companies have achieved higher Revenue quarter on quarter growth. While Maxcyte Inc 's Revenue growth quarter on quarter, overall rank is 3392.


Maxcyte Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 34.37
Y / Y Revenue Growth (TTM) -0.13 %
Year on Year Revenue Growth Overall Ranking # 3432
Seqeuential Revenue Change (TTM) 10.7 %
Seq. Revenue Growth (TTM) Overall Ranking # 3013


Cumulative Revenue growth Comment
Maxcyte Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Maxcyte Inc 's annual Revenue growth would be -0.13% year on year to $34 millions.

In the Healthcare sector 457 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2447 to 3432.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 458
Overall # 3432

Revenue TTM Y/Y Growth Statistics
High Average Low
30.59 %
 -0.13 %
-24.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 414
S&P 500 # 3013
Cumulative Revenue growth Comment
Maxcyte Inc showed decline, but improvement compare to trailing twelve month Revenue decrease in Jun 30 2026. If the fiscal year would end in Sep 30 2026, Maxcyte Inc 's annual Revenue fall would be -0.13% year on year to $34 millions.

In the Healthcare sector 457 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 2447 to 3432.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 28
Healthcare Sector # 458
Overall # 3432

Revenue TTM Y/Y Growth Statistics
High Average Low
30.59 %
-0.13 %
-24.52 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 28
Sector # 414
S&P 500 # 3013




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
MXCT's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue fall for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Vivosim Labs Inc 82.14%$ 82.143 millions
Syndax Pharmaceuticals Inc 81.59%$ 81.592 millions
Iovance Biotherapeutics inc 80.07%$ 80.074 millions
Rhythm Pharmaceuticals Inc 79.59%$ 79.594 millions
Omniab Inc 78.34%$ 78.339 millions
Aclarion Inc 78.09%$ 78.086 millions
Personalis Inc 76.59%$ 76.585 millions
Delcath Systems Inc 76.05%$ 76.047 millions
Mobia Medical Inc 73.28%$ 73.280 millions
Wave Life Sciences Ltd 72.95%$ 72.950 millions
Igc Pharma Inc 71.73%$ 71.728 millions
Phathom Pharmaceuticals Inc 71.14%$ 71.142 millions
Ptc Therapeutics inc 69.57%$ 69.571 millions
Seres Therapeutics Inc 68.95%$ 68.946 millions
Alamar Biosciences Inc 68.46%$ 68.458 millions
Carlsmed Inc 66.74%$ 66.736 millions
Corcept Therapeutics Inc63.97%$ 63.974 millions
Tarsus Pharmaceuticals Inc 63.92%$ 63.921 millions
Tg Therapeutics Inc 60.74%$ 60.743 millions
Heartflow Inc 60.42%$ 60.425 millions
Glaukos Corp59.02%$ 59.021 millions
X4 Pharmaceuticals Inc58.64%$ 58.640 millions
Kiniksa Pharmaceuticals International Plc58.12%$ 58.121 millions
Envoy Medical Inc 57.14%$ 57.143 millions
Humacyte Inc 55.21%$ 55.208 millions
Butterfly Network Inc 53.45%$ 53.453 millions
Avita Medical Inc 53.05%$ 53.054 millions
Immunitybio inc 52.34%$ 52.338 millions
Axsome Therapeutics Inc 51.87%$ 51.873 millions
Innovative Eyewear Inc 51.12%$ 51.123 millions


About Maxcyte Inc Revenue Growth Rates (MXCT), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Maxcyte Inc (CIK 1287098).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001104659-26-125236
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Maxcyte Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.